Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (4163)	3/23/2006 2:43:41 PM
From: nigel bates	Read Replies (1) \| Respond to of 12215

>>.You should also know I don't know anything about the (inside of the) human body.<< Not a medic, or serial killer, then ? :-)

To: keokalani'nui who wrote (4163)	9/12/2006 5:04:22 PM
From: sjemmeri	Respond to of 12215

ACAM news: ACAMBIS PLC (ACAM) Said Novartis agreed to pay the company $19 million in cash to settle a dispute related to the Arilvax yellow- fever vaccine. Also reported positive Phase 2 trial data for its West Nile virus vaccine. Price: $5.60 Net Change: $0.52 % Change: 10.24% Gain Volume: 22,750 Shares

To: keokalani'nui who wrote (4163)	1/17/2007 12:11:19 PM
From: dr.praveen	Read Replies (2) \| Respond to of 12215

GlaxoSmithKline, Novartis, Iomai get H5N1 vaccine contracts Remember our old Iomai:-) Up 25% Edit: Iomai Awarded Government Contract, Totaling $128 Million, to Develop Dose-Sparing Patch for Use in an Influenza Pandemic Wednesday January 17, 11:45 am ET -- Conference Call to Discuss Contract Scheduled for 1 p.m. Eastern -- GAITHERSBURG, Md., Jan. 17 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) today announced it will receive a contract from the Department of Health and Human Services (DHHS) to fund the company's development of a dose-sparing patch for use with a pandemic influenza vaccine. If the product is developed through licensure, the total cost reimbursed by DHHS, plus the fixed fee, is estimated to be $128 million. DHHS has allotted approximately $14.5 million to cover performance under this contract through March 31, 2008. Iomai is developing a skin patch that, when used in conjunction with an injectable influenza vaccine, is designed to stimulate an immune response to even small doses of vaccine. This would allow public health officials to extend vaccine supply in the event of an influenza pandemic. "We believe our novel immune-boosting patch for use with injectable vaccines for pandemic influenza could play a critical role in addressing the growing concern about vaccine supply in the event of a pandemic," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "Unfortunately, history suggests that influenza pandemics are inevitable, and given current concerns about the avian H5N1 strain, we are looking to accelerate the development of this product to help alleviate those supply concerns." During the course of the contract, the company will be reimbursed for research, development and capital costs associated with the preclinical and clinical testing of the immunostimulant patch. Under the contract, Iomai will develop a plan to bring the product to market and move forward to assess the safety and immunogenicity of the patch. The initial funding will be used to show safety and immunogenicity in humans. Stretching the Vaccine Supply Dose-sparing strategies for pandemic influenza could be a significant component of the response to an influenza pandemic. Recent research indicates that even at peak capacity, vaccine production may only be sufficient to vaccinate less than 10 percent of the U.S. population. These concerns prompted DHHS, earlier this year, to call for proposals on ways to "stretch the domestic influenza vaccine supply in the event of an influenza pandemic." Preclinical work suggests that the Iomai patch could cut the vaccine dose needed to provide protection by as much as 10- to 100-fold, helping to address those supply concerns. The Iomai approach uses a potent adjuvant, applied to the skin through a patch that is affixed over the site of the injected vaccine. Once the patch is applied, the adjuvant passes into the skin, targeting cells called Langerhans cells. Those specialized skin cells carry the adjuvant into the lymph nodes, where it works to boost an individual's immune response to the vaccine. This proprietary approach, known as transcutaneous immunization (TCI), has been shown in a clinical study to boost immune responses to traditional influenza vaccines in a group of elderly volunteers. Ideal for Stockpiling The patch is designed to be used in conjunction with any pandemic influenza vaccine. It is also designed to be stored and shipped at room temperature, making the product ideal for stockpiling and rapid distribution. The patch is easily applied, requires no equipment to use and is disposable. In addition to accelerating the pace of research and clinical testing, Iomai will also develop for DHHS a detailed production plan explaining how the company would produce 150 million immunostimulant patches in a six-month period. Though Iomai will soon begin that planning process as laid out by DHHS, the contract announced today does not cover commercial production of the patches; additional funding would be required to produce the patches at the scale needed for stockpiling.